MedPath

INDIUM IN 111 CHLORIDE

Diagnostic - For use only in radiolabeling ProstaScint™ (Capromab Pendetide). Radioimmunotherapy - For use only in radiolabeling Zevalin™ (Ibritumomab Tiuxetan).

Approved
Approval ID

e07e66ef-fb9e-4f9f-b63f-ab28f622cb2e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 19, 2019

Manufacturers
FDA

Curium US LLC

DUNS: 079875617

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

indium in 111 chloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69945-132
Application NumberNDA019841
Product Classification
M
Marketing Category
C73594
G
Generic Name
indium in 111 chloride
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 19, 2019
FDA Product Classification

INGREDIENTS (2)

INDIUM CHLORIDE IN-111Active
Quantity: 10 mCi in 1 mL
Code: 58TD96H03I
Classification: ACTIM
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

INDIUM IN 111 CHLORIDE - FDA Drug Approval Details